Apoptosis, Fas and Fas-ligand expression in melanocytic tumors

Journal of Cutaneous Pathology

Volumn 26, Issue 2, 1999, Pages 72-77

  Sprecher, Eli ^a,c   Bergman, Reuven ^a   Meilick, Ahuvah ^a   Kerner, Hedviga ^a   Manov, Lena ^a   Reiter, Irena ^a   Shafer, Yan ^b   Maor, Gilah ^a   Friedman Birnbaum, Rachel ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b HAEMEK MEDICAL CENTER   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DNA NUCLEOTIDYLEXOTRANSFERASE; FAS ANTIGEN; FAS LIGAND;

APOPTOSIS; ARTICLE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSURVEILLANCE; JUVENILE MELANOMA; MELANOMA; MONONUCLEAR CELL;

ANTIGENS, CD95; APOPTOSIS; FAS LIGAND PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MELANOMA; MEMBRANE GLYCOPROTEINS; NEVUS, EPITHELIOID AND SPINDLE CELL; NEVUS, PIGMENTED; SKIN NEOPLASMS;

EID: 0033014996     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0560.1999.tb01805.x     Document Type: Article

References (28)

1. Wyllie A. Apoptosis: an overview. Br Med Bull 1997; 53: 451.
2. Raskin CA. Apoptosis and cutaneous biology. J Am Acad Dermatol 1997; 36: 885.
3. Kagi D, Lederman B, Burgi K, et al. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Ann Rev Immunol 1996; 14: 207.
4. Leithauser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69: 415.
5. Staunton MJ, Gaffney EF. Tumor type is a determinant of susceptibility to apoptosis. Am J Clin Pathol 1995; 103: 300.
6. Bergman R, Shemer A, Levy R, et al. Immunohistochemical study of p53 protein expression in Spitz nevus as compared with other melanocytic lesions. Am J Dermatopathol 1995; 17: 547.
7. Akslen LA, Monstad SE, Larsen B, et al. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. Int J Cancer 1998; 79: 91.
8. Tang L, Tron VA, Reed JC, et al. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 1998; 4: 1865.
9. Bar-Eli M. Molecular mechanisms of melanoma metastasis. J Cell Physiol 1997; 173: 275.
10. Takaoka A, Adachi M, Okuda H, et al. Anti-cell death activity promotes pulmonary metastasis of melanoma cells. Oncogene 1997; 14: 2971.
11. Glinsky GV, Glinsky VV, Ivanova AB, Hueser CJ. Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett 1997; 115: 185.
12. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor escape. Science 1996; 274: 1363.
13. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493.
14. Oishi M, Maeda K, Sugiyana S. Distribution of apoptosis-mediating Fas antigen in human skin and effects of anti-Fas monoclonal antibody on human epidermal keratinocyte and squamous cell carcinoma cell lines. Arch Dermatol Res 1994; 286: 396.
15. Mooney EE, Ruis Peris JM, O'Neill A, Sweeney EC. Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. J Clin Pathol 1995; 48: 242.
16. Li G, Tang L, Zhou X, Tron V, Ho V. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res 1998; 8: 17.
17. Papoff G, Cascino I, Eramo A, et al. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996; 156: 4622.
18. Natoli G, Ianni A, Costanzo A, et al. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 1995; 11: 1157.
19. Vollmers HP, Dammrich J, Hensel F, et al. Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma. Cancer 1997; 79: 433.
20. Sugahara K, Yamada Y, Higarata Y, et al. Soluble and membrane isoforms of Fas/CD95 in fresh adult T-cell leukemia (ATL) cells and ATL cell lines. Int J Cancer 1997; 72: 128.
21. Rokhlin N, Bishop GA, Hostager BS, et al. Fas-mediated apoptosis in human prostatic cell lines. Cancer Res 1997; 57: 1758.
22. Saenz-Santamaria MC, Reed JA, McNutt NS, Shea CR. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi. J Cutan Pathol 1994; 21: 393.
23. Bergman R, Lurie M, Kerner H, et al. Mode of c-myc protein expression in Spitz nevi, common melanocytic nevi and malignant melanomas. J Cutan Pathol 1997; 24: 219.
24. Bergman R, Kerner H, Manov L, et al. R. c-fos protein expression in Spitz nevi, common melanocytic nevi and malignant melanomas. Am J Dermatopathol 1998; in press.
25. de Vries TJ, Fourkour A, Wobbes T, et al. Heterogeneous expression of immunotherapy candidate proteins gp100, Mart-1 and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 1997; 57: 3223.
26. Bergman R, Dromi R, Trau H, et al. The pattern of HMB-45 antibody staining in compound Spitz nevi. Am J Dermatopathol 1995; 17: 542.
27. Rappl G, Seiter S, Ugurel S, Tilgen W, et al. Fas ligand expression in normal and neoplastic cells of melanocytic origin. J Invest Dermatol 1998; 110: 574A.
28. Harada M, Suzuki M, Ikeda T, et al. Clonality in nevocellular nevus and melanoma: an expression-based clonality analysis at the X-linked genes by polymerase chain reaction. J Invest Dermatol 1997; 109: 656.